Therapeutics that are designed to engage RNA interference (RNAi) pathways have the potential to provide new, major ways of imparting therapy to patients 1,2 . Long, double-stranded RNAs were first shown to mediate RNAi in Caenorhabditis elegans 3 , and the potential use of RNAi for human therapy has been demonstrated by the finding that small interfering RNAs (siRNAs; approximately 21base-pair double-stranded RNA) can elicit RNAi in mammalian cells without producing an interferon response 4 . We are at present conducting the first in-human phase I clinical trial involving the systemic administration of siRNA to patients with solid cancers using a targeted, nanoparticle delivery system. Here we provide evidence of inducing an RNAi mechanism of action in a human from the delivered siRNA. Tumour biopsies from melanoma patients obtained after treatment show the presence of intracellularly localized nanoparticles in amounts that correlate with dose levels of the nanoparticles administered (this is, to our knowledge, a first for systemically delivered nanoparticles of any kind). Furthermore, a reduction was found in both the specific messenger RNA (M2 subunit of ribonucleotide reductase (RRM2)) and the protein (RRM2) levels when compared to pre-dosing tissue. Most notably, we detect the presence of an mRNA fragment that demonstrates that siRNA-mediated mRNA cleavage occurs specifically at the site predicted for an RNAi mechanism from a patient who received the highest dose of the nanoparticles. Together, these data demonstrate that siRNA administered systemically to a human can produce a specific gene inhibition (reduction in mRNA and protein) by an RNAi mechanism of action.
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A major challenge with the use of siRNAs in mammals is their intracellular delivery to specific tissues and organs that express the target gene. The first demonstrations of siRNA-mediated gene silencing in mammals through systemic administration were accomplished using naked siRNA and methods of administration not compatible with clinical application [5] [6] [7] . Since then, several delivery vehicles have been combined with siRNAs to improve their delivery in animal models 1, 2 . A recent study provided direct evidence for the siRNA mechanism of action by using a modified 59-RACE (rapid amplification of complementary DNA ends) PCR technique providing positive identification of the specific mRNA cleavage product 8 . Human clinical trials with synthetic siRNAs began in 2004, using direct intraocular siRNA injections for patients with blinding choroidal neovascularization (CNV). Subsequently, other clinical trials have initiated 2 and early clinical data are beginning to appear 9, 10 . Although there are animal studies that do support the possibility of an RNAi mechanism of action from administered siRNA 11 , other animal data from siRNAs injected into the eyes of mice for the treatment of CNV suggest non-RNAi mechanisms of action for CNV suppression 12 . At this time, no direct evidence for an RNAi mechanism of action in humans from siRNA administered either locally or systemically has been reported.
We are at present conducting the first, to our knowledge, siRNA clinical trial that uses a targeted nanoparticle-delivery system (clinical trial registration number NCT00689065) 13 . Patients with solid cancers refractory to standard-of-care therapies are administered doses of targeted nanoparticles on days 1, 3, 8 and 10 of a 21-day cycle by a 30-min intravenous infusion. The nanoparticles consist of a synthetic delivery system ( Fig. 1a ) containing: (1) a linear, cyclodextrin-based polymer (CDP), (2) a human transferrin protein (TF) targeting ligand displayed on the exterior of the nanoparticle to engage TF receptors (TFR) on the surface of the cancer cells, (3) a hydrophilic polymer (polyethylene glycol (PEG) used to promote nanoparticle stability in biological fluids), and (4) siRNA designed to reduce the expression of the RRM2 (sequence used in the clinic was previously denoted siR2B15) 14 . The TFR has long been known to be upregulated in malignant cells 15 , and RRM2 is an established anti-cancer target 16 . These nanoparticles (clinical version denoted as CALAA-01) have been shown to be well tolerated in multi-dosing studies in non-human primates 17 . Although a single patient with chronic myeloid leukaemia has been administered siRNA by liposomal delivery 18 , our clinical trial is the initial human trial to systemically deliver siRNA with a targeted delivery system and to treat patients with solid cancer 13 .
To ascertain whether the targeted delivery system can provide effective delivery of functional siRNA to human tumours, we investigated biopsies from three patients from three different dosing cohorts; patients A, B and C, all of whom had metastatic melanoma and received CALAA-01 doses of 18, 24 and 30 mg m 22 siRNA, respectively. Given the highly experimental nature of this protocol, the regulatory process at both the local and federal levels explicitly precluded a provision for mandatory biopsies in all patients. Therefore, biopsies were obtained on a voluntary basis. Biopsies in these three patients were collected after the final dose of cycle 1 (denoted A post , B post and C1 post ) and compared to archived tissue (denoted A pre , B pre and C1 pre ). Patient C continued therapy beyond one cycle and provided another set of biopsy material (C2 pre that was obtained approximately 1 month after the final dose of cycle 1, and C2 post that was collected on the day of the final dose of cycle 2). Because of the limited sample amount, only immunohistochemistry (IHC) and staining for the nanoparticles could be performed on the C1 pre and C1 post samples, and protein (for western blot analyses) was only available from the C2 pre and C2 post samples. Details of this clinical trial will be reported elsewhere when completed.
The targeted nanoparticles (about 70-nm diameter) were administered intravenously, as they are designed to circulate and then to accumulate and permeate in solid tumours 13 . Within the tumour, the TF-targeting ligand assists in directing the nanoparticles into tumour cells overexpressing TFR 19 . To detect the nanoparticles in tumour cells, sections of the tumour tissue were stained for the presence of the nanoparticles using a 5-nm gold particle that is capped with thiolated PEG containing adamantane (AD) at the end distal to the thiol (AD-PEG-Au) to allow for multivalent binding to the cyclodextrins (Supplementary Scheme 2). The function of the stain has been previously confirmed using other cyclodextrin-containing particles 20 , and is demonstrated here for the targeted nanoparticles carrying siRNA in vitro ( Supplementary Fig. 1 ) and in vivo ( Supplementary Figs 2 and 3 ). Transmission electron microscopy (TEM) images of the nanoparticles confirm that in mice, the nanoparticles are intracellular (Supplementary Fig. 2 ). Samples A, B and C1, analysed in a blinded fashion, demonstrated a heterogeneous distribution of nanoparticles only in post-dosing tumour tissue ( Fig. 1 for post-dosing and Supplementary  Fig. 4 for pre-dosing). The nanoparticles can localize intracellularly in tumour tissue and are not found in the adjacent epidermis ( Fig. 1 ). In these biopsies TEM images were dominated by melanosomes 21 inhibiting the identification of the nanoparticles (data not shown). Samples C1 post and C2 post show the highest number and intensity of stained regions, B post shows a decreased amount of staining relative to samples C1 post and C2 post (Fig. 1b) , A post does not show the presence of the stain (Fig. 1b) , and all the pre-dosing samples are completely negative for the stain ( Supplementary Fig. 4 ). This is the first example of a dosedependent accumulation of targeted nanoparticles in tumours of humans from systemic injections for nanoparticles of any type.
Tumour RRM2 mRNA levels were measured by quantitative realtime reverse-transcriptase polymerase chain reaction (qRT-PCR) and were performed in a blinded fashion 22 . Reduction in RRM2 mRNA is observed in the post-treatment samples (Fig. 2 ). Because samples A pre and B pre are from tissues collected many months before the initiation of siRNA treatment, the fraction of the overall reduction in mRNA observed in A post and B post attributable to the nanoparticle treatment cannot be directly ascertained. Unfortunately, we were not able to perform PCR on the C1 samples. However, the PCR data from the C2 pre and C2 post samples (collected 10 days apart) provide direct evidence for RRM2 mRNA reduction by the treatment of the patient with the nanoparticles.
To ascertain whether the RRM2 protein level is reduced in the tumour because of the siRNA treatment, IHC and western blotting were used as previously described in mice 23 . Because RRM2 protein expression is largely restricted to the late G1/early S phase of the cell cycle, not all of the tumour cells will be expressing RRM2. Figure 3 shows IHC data for RRM2 and TFR proteins in C1 pre and C1 post samples (IHC analyses were performed in a blinded fashion and ten random regions of each sample were analysed). Considerable reduction in RRM2 is observed (mean scoring of RRM2 from the ten sections was reduced fivefold) after treatment, whereas TFR levels are slightly increased (mean scoring of TFR from the ten sections was increased 1.2-fold) in the C1 pre and C1 post samples. The low level of RRM2 that is observed by IHC in the C1 post sample is maintained in the C2 pre and C2 post samples (by IHC). Western blot analyses of the C2 pre and C2 post samples show a reduction in the level of the RRM2 protein that is due to the siRNA treatment (RRM2 mRNA reductions exceeded the reduction levels obtained from protein but this could be due to post-transcriptional mechanisms that have been observed previously 24 ). The decreases in the RRM2 mRNA and protein observed after treatment (Fig. 2b) suggest the siRNA treatment remains effective after several cycles of dosing. The IHC data from patient A do not show changes in RRM2 expression after dosing, whereas results from patient B are indicative of reductions in maximal RRM2 expression (IHC scoring of the regions of maximal expression showed a 1.5-fold decrease), but the overall mean expression levels remained relatively constant (IHC scoring of the ten sections).
To demonstrate that the siRNA delivered by the targeted nanoparticles can engage the RNAi machinery, the mRNA cleavage products were characterized using a modified 59-RNA-ligand-mediated RACE (59-RLM-RACE) PCR technique (Fig. 4 ). An RRM2 mRNA fragment-the 59 end of which matches the predicted cleavage site (ten base pairs (bp) from the 59 end of the antisense strand)-was detected in the C2 pre and C2 post samples, but not in B post and A post or their corresponding pre-treatment samples. RACE does not provide a quantitative measure of the amount of the fragments so the intensities of the bands cannot be correlated with the amounts in the tissue samples. The presence of this RRM2 mRNA fragment from patient C indicates that siRNA delivered by targeted nanoparticles can engage the RNAi machinery in a solid human tumour and induce the desired mRNA cleavage. Furthermore, this result indicates that at least a portion of the RRM2 mRNA and protein reductions observed from the C2 samples are due to a bona fide RNAi mechanism. The presence of the RRM2 mRNA fragment in the C2 pre sample suggests that siRNA can provide an RNAi mechanism for several weeks (mRNA cleavage in the C2 pre sample must originate from cycle one dosing) as the RRM2 protein levels remained relatively constant when compared to the C1 post sample (IHC). We have shown that the length of the RNAi effects of delivered siRNA in both cells and animals (mice) is dependent on the doubling time of the cells being analysed (longer inhibition times with longer cell doubling times) 25 . Gene silencing by siRNA can occur on the timescale observed here, approximately 1 month, provided the cell doubling times are long 25 . Patient C had stable disease between these biopsies, and these mostly quiescent tumours have very slow growth kinetics that would be suitable to experience lengthy RNAi effects 25 . Furthermore, we do not know how long the nanoparticles reside within the cells and release siRNA. Because the nanoparticles are observed in the sample C1 post and not the sample C2 pre , they must disassemble within 1 month. Thus, the pharmacodynamics of the RNAi effects could be due to the combination of the nanoparticle disassembly time and the time that the siRNA resides within the RNAi machinery.
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Predicted siRNA-cleavage site administered siRNA. Moreover, these data demonstrate the first example of dose-dependent accumulation of targeted nanoparticles in human tumours. The reduction of the RRM2 mRNA and protein by the RRM2-specific siRNA is observed, and the results from 59-RLM-RACE analyses show that the delivered siRNA engages the RNAi machinery. These data demonstrate that RNAi can occur in a human from a systemically delivered siRNA, and that siRNA can be used as a gene-specific therapeutic.
METHODS SUMMARY
Detection of targeted nanoparticles in biopsy samples. Snap-frozen patient biopsy samples were embedded in Tissue-Tek O.C.T. compound (Sakura) for the generation of 6-mm-thick cryosections. After immersion in PBS at 37 uC for 1 h to remove any surface O.C.T., and subsequent fixation with acetone at 220 uC for 20 min to permeabilize the cell membrane, sections received staining of PEGylated, AD-modified gold nanoparticles (Au-PEG-AD; see Supplementary Information for a description of their preparation) in the dark for 2 h. Brief rinses with PBS were used to remove any non-specifically bound Au-PEG-AD before mounting with ProLong Gold antifade reagent and staining with 49,6-diamidino-2-phenylindole (DAPI; Invitrogen). A Zeiss LSM 510 confocal scanning microscope was used to collect the images (DAPI-excitation: 370 nm, emission: 440 nm; Au-PEG-AD-excitation: 488 nm, emission: 507 nm). 59-RLM-RACE. 59-RLM-RACE was performed according to the Invitrogen GeneRacer manual with modifications. Two-to-eight micrograms of total RNA was ligated directly to 250 ng GeneRacer RNA adaptor using T4 RNA ligase. After phenol extraction and ethanol precipitation, the purified ligation products were reverse-transcribed using SuperScriptIII (Invitrogen) and an RRM2 genespecific reverse-transcription primer (59-CTCTCTCCTCCGATGGTTTG-39). 59-RLM-RACE PCR was performed using the GeneRacer 59 and an RRM2 gene-specific reverse primer (59-GGCCAGGCATCAGTCCTCGTTTCTTG-39). PCR was performed using a Bio-Rad MJ Mini personal thermocycler using PCR conditions of 95 uC for 3 min (1 cycle), 95 uC for 30 s, 60 uC for 30 s, 72 uC for 1 min (40 cycles), 72 uC for 10 min (1 cycle). A second round of nested PCR was then performed using the GeneRacer 59 nested primer and an RRM2 gene-specific nested primer (59-GGCCCAGTCTGCCTTCTTCTTGAC-39). PCR products were run on a 2% agarose gel and stained with 1 mg ml 21 ethidium bromide. PCR products were excised from the gel and sequenced directly to confirm RACE band identities.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
